Mildronate (Meldonium Dihydrate)

Meldonium Dihydrate inhibits carnitine synthesis, reducing fatty‑acid oxidation and favoring glucose oxidation in heart muscle cells. This metabolic shift lowers oxygen demand, enhances ATP production efficiency, and protects myocardial tissue during periods of reduced blood flow.

The dosage of Mildronate is determined by the prescribing healthcare professional based on the individual patient's condition, severity, and response to therapy. Patients should follow the prescriber's instructions and not adjust the dose on their own.

Mildronate should be used during pregnancy or lactation only if the potential benefits justify the possible risks to the fetus or infant. Healthcare providers must evaluate each case carefully before prescribing the medication to pregnant or nursing women.

To place an order, submit an enquiry on the Mildronate product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Mildronate uniquely targets carnitine biosynthesis, offering a distinct mechanism compared with agents that primarily act as vasodilators or beta‑blockers. Its metabolic effects can complement other cardiovascular drugs, but comparative efficacy and safety should be assessed by the treating physician.

Mildronate tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the product’s stability and potency.

Mildronate is supplied as oral tablets and is taken by mouth with water, typically under the guidance of a healthcare professional. The exact administration schedule is determined by the prescriber based on the patient’s therapeutic needs.

Serious risks include severe allergic reactions such as anaphylaxis, cardiac arrhythmias, significant hypotension, and rare but serious skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Mildronate is contraindicated in patients with known hypersensitivity to Meldonium or any tablet excipients, and should be avoided in individuals with severe hepatic impairment, uncontrolled hypotension, or those taking monoamine oxidase inhibitors without medical supervision.